- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
E-Z-EM introduces new bowel agent
Gastrointestinal contrast agent developer E-Z-EM of Westbury,NY, has introduced a new product targeted at improving visualizationof the small bowel in x-ray studies. E-Z-EM's Entero Vu agentenables "see-through" imaging of the small bowel,
Gastrointestinal contrast agent developer E-Z-EM of Westbury,NY, has introduced a new product targeted at improving visualizationof the small bowel in x-ray studies. E-Z-EM's Entero Vu agentenables "see-through" imaging of the small bowel, inwhich the translucency of the intestine is maintained even throughmultiple organ layers. Entero Vu allows radiologists to obtaina clear study of the entire small bowel, according to the company.
E-Z-EM claims that Entero Vu offers clearer images than small-bowelstudies using conventional oral contrast media, which often lackdefinition and detail because of the high density of the media.Because it is administered orally, Entero Vu is also easier tohandle than another small-bowel imaging procedure, enteroclysis,in which contrast is directly infused into the small intestinevia a catheter.
E-Z-EM has set a list price of $198 for a box of Entero Vu, whichconsists of 12 doses.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
